Tissue Regenix Group plc EBIT

Tissue Regenix Group plc posts a EBIT of $-500K as of June 2024. That compares with $-11M in the prior-year period — up 95.6% year over year. That is above the sector sector average of $-77M. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Tissue Regenix Group plc's EBIT was $-11M. The latest reading is $-500K — a 95.6% year-over-year increase (period ending June 2024). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a EBIT near $-77M is typical. Tissue Regenix Group plc's $-500K is higher that level. That is roughly 99.4% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

EBIT is one piece of Tissue Regenix Group plc's financial statement story. At $-500K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for TSSNF's EBIT usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $-77M), and (3) consistency with growth and profitability. This page covers the first two; Tissue Regenix Group plc's other metric pages and overview cover the third.